Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The cellular and molecular mechanisms underlying the health impacts of climate change must be better understood in order to plan interventions that mitigate harm.
The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.
In healthcare, many artificial intelligence models could be used in settings other than those for which they were approved. But such off-label use must include an empirical or mechanistic evaluation to ensure patient safety.
The European Union’s new AI Act focuses on risk without considering benefits, which could hinder the development of new technology while failing to protect the public.
Steatotic liver disease is part of a revised nomenclature to replace the term fatty liver disease, but this should also drive forward innovation in research, diagnostics and treatments.
Automated insulin delivery systems have transformed the care of people living with type 1 diabetes and continue to move closer to the ultimate goal of a fully autonomous artificial pancreas.
Community screening could be used for the monitoring, early detection and prevention of for depression, and to maximize the effects of the policies to reduce its burden.
Drawing from real-life scenarios and insights shared at the RAISE (Responsible AI for Social and Ethical Healthcare) conference, we highlight the critical need for AI in health care (AIH) to primarily benefit patients and address current shortcomings in health care systems such as medical errors and access disparities.
The All of Us Research Program has prioritized the enrollment of people from backgrounds that are historically under-represented in medical research to bring precision medicine to the full diversity of the US population and to improve health outcomes for all.
Policy responses should be based on the known characteristics of an emerging pathogen with pandemic potential and the tools available to tackle it, rather than on specific known pathogens.
Electronic health information, including from electronic health records, is needed to develop AI tools for health, but the seamless flow of data will require standards and interoperability.
Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.
DigiONE is a pilot European learning health system in precision oncology that aims to identify optimal cancer treatments by learning from every patient, not just those in trials, through privacy-preserving interrogation of their standardized routine electronic health records.
A six-tiered governance framework for federated health data, with varying levels of data access and sharing, is proposed to facilitate the use of health data held within more than one secure environment, while preserving privacy.
Therapeutic genome editing has great potential to cure some rare diseases, but germline editing is banned. With a broad societal discussion supported by national and transnational legislation, it could be allowed in certain circumstances.
GLP-1 receptor agonists are effective treatments for obesity but are less accessible worldwide than pharmacological treatments for diabetes, reflecting biases and lack of education, and perpetuating health inequalities.
Resilience for future pandemics requires increased research and development, sustained vaccine manufacturing capabilities and global public–private collaboration.